Can I Take Glutathione With PT-141 (Bremelanotide)?

What Is PT-141 (Bremelanotide) and Why Do Women Take It?

PT-141, sold as Vyleesi, is a melanocortin receptor agonist approved by the FDA in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works differently from every other sexual-health drug on the market. Rather than acting on genitals or blood vessels, bremelanotide binds to melanocortin receptors in the central nervous system, particularly MC3R and MC4R, to increase sexual motivation at the brain level.

Women self-administer it as a 1.75 mg subcutaneous injection into the abdomen or thigh at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours, and no more than one dose per eight days, is recommended.

Why premenopausal women specifically?

The two key trials that supported FDA approval, RECONNECT study 301 and 302, enrolled premenopausal women with generalized, acquired HSDD. Postmenopausal women were excluded. Statistically significant increases were seen in the desire domain of the Female Sexual Function Index and in a measure called the Female Sexual Distress Scale-Desire/Arousal/Orgasm. The effect size was modest: approximately 0.5-point improvement on a 1.2-point scale compared with placebo over 24 weeks. Real. Measurable. Not dramatic.

Off-label use

Some clinicians prescribe bremelanotide off-label for postmenopausal women with HSDD or for men with erectile dysfunction, but no large randomized controlled trial data in these groups exists. Women considering off-label use should be told directly that the evidence base is thin for any population outside the RECONNECT trials.

What Is Glutathione and Why Do Women Take It?

Glutathione is a tripeptide made from glycine, cysteine, and glutamate. Your body synthesizes it endogenously, primarily in the liver, where it is the most abundant intracellular antioxidant. Women take supplemental glutathione for a wide range of reasons: skin brightening, liver support, antioxidant replenishment during oxidative stress states such as PCOS, and general "detox" protocols that have become common in functional-medicine and telehealth settings.

Oral glutathione absorption has historically been considered poor, though a 2015 randomized trial in Nutrition Journal demonstrated that 500 mg per day of oral reduced glutathione for six months measurably increased whole-blood glutathione compared with placebo. Liposomal and sublingual forms may offer better absorption. Intravenous glutathione is used in some IV-drip clinics, often in the same aesthetic-medicine settings where peptides like PT-141 are discussed.

Glutathione and the liver

The liver connection matters here. Glutathione is central to Phase II hepatic detoxification, where it conjugates electrophilic compounds to make them water-soluble for excretion. Any compound that is metabolized by the liver, or any supplement that meaningfully changes hepatic glutathione status, could theoretically alter how other drugs are processed. That theoretical concern is where most of the "interaction" question originates.

Does Glutathione Interact With PT-141? The Pharmacology Explained

The short answer is that no documented pharmacokinetic interaction between glutathione and bremelanotide has been published in the peer-reviewed literature as of mid-2025.

To understand why that answer is both reassuring and incomplete, it helps to look at how each substance is actually metabolized.

How bremelanotide is metabolized

Bremelanotide does not appear to be a significant substrate, inhibitor, or inducer of the major cytochrome P450 (CYP) enzymes. The FDA label states that in vitro studies found no clinically relevant CYP interactions. The drug is hydrolyzed nonspecifically, meaning multiple peptidases in plasma and tissues break it down rather than one specific enzymatic pathway. Its half-life is approximately 2.7 hours.

How glutathione affects drug metabolism

Glutathione participates in Phase II conjugation reactions but does not directly regulate CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 activity in any clinically established way at supplemental doses. A woman taking 500 mg to 1,000 mg of oral or liposomal glutathione is not going to materially alter the peptidase activity that breaks down bremelanotide. The metabolic pathways simply do not overlap in a way that would slow or speed up bremelanotide clearance.

Pharmacodynamic considerations

A pharmacodynamic interaction would mean the two substances affect the same biological target or produce competing or additive physiological effects. Bremelanotide acts on central melanocortin receptors. Glutathione is an antioxidant operating at the level of oxidative-stress buffering and glutathione-S-transferase activity. These mechanisms are not on the same pathway. No data from animal models or human trials suggests a meaningful pharmacodynamic interaction.

The one area worth watching: blood pressure

Bremelanotide transiently raises blood pressure after injection, typically by 2 to 4 mmHg systolic, peaking at about 4 hours post-dose and resolving within 12 hours. Intravenous glutathione given at high doses has been studied for its vasodilatory effects in some contexts. The clinical data on IV glutathione and blood pressure is preliminary and applies to therapeutic IV doses far above typical supplement use. If you are receiving high-dose IV glutathione infusions through a clinic and also using PT-141, mention both to your prescriber so blood pressure can be discussed. This is a precaution, not a documented interaction.

Sex-Specific Physiology: How Your Hormones Affect Both Substances

Women's hormonal status changes glutathione metabolism and oxidative stress in ways that most "supplement interaction" resources ignore. Here is a stage-by-stage framework specific to women.

Reproductive years (cycling women)

Estrogen has antioxidant properties and upregulates glutathione synthesis in several tissues. Your endogenous glutathione levels naturally fluctuate across your menstrual cycle. During the luteal phase, progesterone-dominant environment, there is some evidence of increased oxidative stress compared with the follicular phase, which may explain why some women feel they respond better to antioxidant supplementation at certain cycle points. For PT-141, the RECONNECT trials did not report cycle-phase-specific response data, so we do not know whether bremelanotide works better at one point in the cycle than another.

PCOS

Women with polycystic ovary syndrome have measurably lower glutathione levels and higher oxidative stress markers compared with women without PCOS. Glutathione supplementation is sometimes used in PCOS management, alongside insulin-sensitizing agents. HSDD is also more common in women with PCOS, partly due to hormonal disruption and partly due to the psychological burden of the condition. A woman with PCOS who is prescribed PT-141 for HSDD might also independently be using glutathione. The combination is plausible, and currently no evidence suggests it is dangerous.

Perimenopause

PT-141 is not approved for perimenopausal or postmenopausal women, but off-label use happens. Perimenopausal estrogen fluctuations are associated with worsening oxidative stress, declining libido, and changes in central neurotransmitter systems. The ACOG and The Menopause Society both note that HSDD is highly prevalent in this group. Using PT-141 off-label in perimenopause is a clinical decision that should include a frank conversation about the absence of trial data in this population.

Post-menopause

Glutathione levels decline with age. Some postmenopausal women use glutathione for skin, metabolic, or general antioxidant reasons. If PT-141 is being considered off-label in this population, the blood-pressure monitoring concern is particularly relevant because baseline cardiovascular risk is higher after menopause.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

PT-141 is contraindicated in pregnancy. This is not a precautionary footnote. The FDA label explicitly states that bremelanotide should not be used in pregnancy, and the drug's prescribing information requires that women who could become pregnant use effective contraception.

Animal data

Animal reproductive studies showed fetal harm at doses that produced systemic exposure in the same range as the human dose. The mechanism relates to melanocortin receptor stimulation, which may affect fetal development. Human data is absent because pregnant women were excluded from all trials.

What to do if you become pregnant on PT-141

If you discover you are pregnant while using bremelanotide, stop immediately and contact your OB-GYN. Enroll in the Vyleesi pregnancy exposure registry at 1-833-984-0168 so that outcomes can be tracked. The FDA registry exists precisely because the human pregnancy data is missing.

Before trying to conceive

Discontinue PT-141 at least one complete menstrual cycle before attempting conception. This washout period is recommended to minimize any residual exposure during early implantation.

Lactation

Whether bremelanotide transfers into breast milk is unknown. No human lactation studies have been conducted. Given the absence of data and the known fetal-harm signal from animal studies, avoid PT-141 while breastfeeding.

Glutathione in pregnancy

Glutathione itself has a different risk profile. Endogenous glutathione is essential for normal fetal development. Some small studies have explored N-acetylcysteine, a glutathione precursor, in pregnancy for conditions like preterm labor and recurrent miscarriage, though findings are mixed and not practice-changing. Supplemental oral glutathione at standard doses has not been studied rigorously in pregnant women. The safest approach is to discuss any supplement with your midwife or OB-GYN before continuing during pregnancy.

Who Should and Should Not Combine These Two

Reasonable candidates for concurrent use

A premenopausal woman using PT-141 as prescribed for diagnosed HSDD who also takes oral or liposomal glutathione at standard supplemental doses (250 mg to 1,000 mg daily) is not taking a combination with a known dangerous interaction. She should:

• Disclose both to her prescriber.
• Monitor blood pressure after each PT-141 injection, particularly if she receives any form of IV glutathione.
• Not use PT-141 more frequently than the label allows regardless of any supplement she is taking.

Women who should exercise more caution

Women receiving high-dose IV glutathione infusions. The dose of glutathione administered intravenously in some aesthetic clinics can be dramatically higher than oral supplemental doses. Until more data exists, use these IV infusions on separate days from PT-141 injections and report any blood pressure changes.

Women with uncontrolled hypertension. Bremelanotide is contraindicated in women with known cardiovascular disease or uncontrolled hypertension. Adding any vasoactive supplement to this picture requires medical clearance.

Women taking antihypertensives. Bremelanotide's transient blood pressure elevation may interact with antihypertensive medication timing. Glutathione is not the concern here; the PT-141 itself is.

Women who are pregnant or breastfeeding. Neither PT-141 nor high-dose supplemental glutathione has established safety in these populations. PT-141 is outright contraindicated.

Monitoring and Practical Guidance

If you are already taking both, here is a step-by-step approach drawn from the prescribing information and general pharmacological principles.

Track your blood pressure

Check blood pressure at baseline before your first PT-141 injection and again at roughly four hours after injection, when the transient blood pressure effect peaks. If you are also receiving IV glutathione, avoid scheduling infusions within 24 hours of a PT-141 dose until you have established your individual blood pressure response to each.

Document your doses

Write down the date, dose, and timing of every PT-141 injection and every glutathione dose, whether oral, liposomal, or IV. This record is useful if your prescriber needs to troubleshoot any symptom.

Report nausea carefully

The most common side effect of PT-141 is nausea, occurring in approximately 40% of women in the RECONNECT trials. Glutathione at high doses can also cause gastrointestinal symptoms in some people. If you experience significant nausea after combining them, report it and consider separating the timing by 24 to 48 hours to identify which agent is responsible.

Ask your prescriber about flushing

Bremelanotide causes flushing in a substantial proportion of users. Glutathione is sometimes marketed as reducing skin pigmentation through antioxidant mechanisms. These are different biological processes, but the combination has not been studied. There is no reason to expect a dangerous interaction, but the lack of data means you are operating with incomplete information, which your prescriber should acknowledge.

The Evidence Gap: What We Do Not Know

Women have been systematically underrepresented in pharmacological interaction research. Most drug-supplement interaction databases rely on studies conducted in predominantly male populations, then extrapolated to women.

For this specific combination, the honest answer is:

• No human pharmacokinetic interaction study has been conducted.
• No case reports of adverse events from this combination appear in the published literature.
• The mechanistic rationale for a clinically significant interaction is weak.
• The absence of evidence is not the same as evidence of absence.

The FDA Drug Interaction guidance applies primarily to prescription drugs interacting with other prescription drugs via CYP pathways. Supplement interactions occupy a regulatory gray zone. Natural Medicines (formerly Natural Medicines Comprehensive Database) rates many supplement-drug interactions on a scale from "minor" to "contraindicated," but glutathione and bremelanotide do not have a specific interaction rating because the combination has not been evaluated.

A 2023 review in Nutrients examining glutathione supplementation across multiple health conditions found no documented interactions with peptide drugs, but the review was not designed to look for this specifically.

The direct quote from the Vyleesi prescribing information on drug interactions reads: "No in vivo drug interaction studies have been conducted" beyond a specific study on naltrexone, which showed no clinically meaningful interaction. Glutathione is not mentioned because it was never tested.

What to Tell Your Prescriber

When you speak with whoever is prescribing your PT-141, the most useful thing you can say is not "I read there's no interaction." The most useful thing is to give complete information and ask the right questions.

Say:

• "I am taking [dose and form] of glutathione [frequency and route]."
• "I want to know if there is any reason you would adjust the timing or monitoring for my PT-141 given this."
• "I want my blood pressure checked before and after my first injection."

Ask:

• "Am I a candidate for this drug given my full health history?"
• "What symptoms should prompt me to contact you after an injection?"
• "Is there any new data on drug-supplement interactions with bremelanotide since the label was written?"

The FDA approval of Vyleesi was accompanied by a REMS (Risk Evaluation and Mitigation Strategy) specifically because of the cardiovascular signal. Your prescriber should be following up on blood pressure regardless of what supplements you take.